Tesamorelin is approved with strong evidence and barely gets mentioned. Why?

Tesamorelin is one of the very few on this site that is approved with evidence: strong. It reduces visceral fat specifically, measured on CT rather than by tape measure, which is a considerably better endpoint than most things get.

It is also almost never discussed. Compare the volume on compounds with no human data at all.

Three reasons, and they are all structural rather than about the drug.

The indication is narrow. Approved for visceral fat in HIV-related lipodystrophy. That is a specific population and most people reading this are not in it.

It is prescribable. Which means the conversation happens with a clinician rather than on a forum. Forums fill the space where there is no clinician to ask.

It is expensive and daily. A daily subcutaneous injection is a real commitment relative to a weekly one.

None of those are "it does not work". It works — that is what strong means, and the visceral fat reduction is measured properly.

And there is a lesson in it, which is that the compounds that generate the most forum activity are selected for by absence rather than by efficacy.

No approval, no prescriber, no completed trial, therefore no authoritative source, therefore a forum. The discussion volume is a measure of the evidentiary vacuum, not of how well anything works.

Tesamorelin has a prescriber. So there is nothing for a forum to do.

That is bleak and I think correct. The busiest threads on any forum like this are about the compounds nobody can tell you about.

Its safety notes are also instructive read against the ipamorelin ones — raises blood sugar, care in diabetes, IGF-1 monitored during treatment, avoided in active cancer and in pregnancy.

Same mechanistic family, same cautions. The difference is that with tesamorelin somebody is monitoring the IGF-1.

"The difference is that somebody is monitoring" is the difference in most of these threads, now I think about it.